Novo teams up with Anthropic on AI-driven drug discovery, Sling Therapeutics and Circle Pharma close major financing rounds, and IQVIA's Phil Ford makes the case for reimagining medical content as a loop rather than a pipeline.
|Articles|October 28, 2015
Valeant Responds to Drug Distribution Criticisms
Author(s)Randi Hernandez
October 28, 2015.
Advertisement
According to a recent report from Citron Research originally highlighted in the New York Times (Oct. 19, 2015), Valeant is using phantom drug distribution companies to manipulate distribution numbers to auditors. Philidor Rx Services came on the
BioPharm International's Randi Hernandez reports on
Advertisement
Related to this article
Novo partners with Anthropic to deploy Claude for targeted drug discovery workflows and AI-driven software development.
How the shifting tides in information consumption are resetting expectations for pharma in providing and delivering health education.
Pharma brands with all the right information are still invisible to AI — and why silence is the bigger risk than inaccuracy.
Pharma has digitized nearly everything — but contract management remains fragmented, creating compliance risk and slowing execution across the enterprise.
The advantages of synthetic advisory boards in stress-testing hypotheses and iterating across a greater scope of scenarios than live boards allow.
As leaders, we must evaluate solutions to fragmentation by asking
the right questions.
Advertisement
Advertisement
Trending on PharmExec
1
M&A Roundup: Lisata Therapeutics Acquires Marea Therapeutics, mAbxience Enters Collaboration with Sandoz
2
The Battle to Own the GLP-1 Patient Journey
3
Pharmaceutical Executive Daily: FDA Approves Fayuvi
4
FDA Approves Kerendia for Adults with Chronic Kidney Disease and Type 1 Diabetes
5